<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04838990</url>
  </required_header>
  <id_info>
    <org_study_id>2157/2020</org_study_id>
    <nct_id>NCT04838990</nct_id>
  </id_info>
  <brief_title>TELEMS: Feasibility of Remote Patient Visits in MS</brief_title>
  <acronym>TELEMSRCT</acronym>
  <official_title>TELE MS RCT: A Randomized Controlled Trial to Evaluate Feasibility of Remote Patient Visits in People With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trials randomizes patients with multiple sclerosis (MS, pwMS) to a remote visit (via&#xD;
      phone or videochat) or a regular outpatient visit. Outcomes include satisfaction on the&#xD;
      patients' and doctor's side.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Actual">October 1, 2021</completion_date>
  <primary_completion_date type="Actual">August 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TMPQ</measure>
    <time_frame>1 week after intervention</time_frame>
    <description>Telemedicine Perception questionnaire (17-85, higher scores are better)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PPSM</measure>
    <time_frame>1 week after intervention</time_frame>
    <description>Patient and Physician Satisfaction with monitoring (6-30, higher scores are better)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physical disability</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>Based on the EDSS (Expanded Disability Status Scale, 0-10, higher scores indicate greater disability)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>conventional visit</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Regular outpatient visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>phone visit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remote visit via phone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>video visit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remote visit via videochat</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EDSS</intervention_name>
    <description>Neurological Exam - EDSS (Expanded Disability Status Scale)</description>
    <arm_group_label>conventional visit</arm_group_label>
    <arm_group_label>phone visit</arm_group_label>
    <arm_group_label>video visit</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Discussion of symptoms</intervention_name>
    <description>Patients will be asked about their wellbeing</description>
    <arm_group_label>conventional visit</arm_group_label>
    <arm_group_label>phone visit</arm_group_label>
    <arm_group_label>video visit</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  confirmed diagnosis of any type of MS&#xD;
&#xD;
          -  own a phone/smartphone/computer&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  language barriers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Altmann, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 21, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Patrick Altmann MD PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>multiple sclerosis</keyword>
  <keyword>remote visits</keyword>
  <keyword>telemedicine</keyword>
  <keyword>remote patient monitoring</keyword>
  <keyword>remote monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Data will be shared upon reasonable request and through our local ERB.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

